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History of present illness 
This is a 37-year-old man with a history of primary antiphospholipid syndrome (APS), with 
clinical manifestations including recurrent venous thrombosis, lower-extremity ulceration, and 
toe ischemia.  He also had history of thrombocytopenia and seizure disorder.    Labs were 
consistent with APS including prolonged dilute Russell's viper venom time (dRVVT), which was 
resistant to phospholipid quenching, as well as an abnormal hexagonal phase phospholipid 
neutralization assay.  He also had high levels of both IgG anticardiolipin and IgG anti-β2GPI 
(both consistently >40 GPL).  All of these labs were durably positive over many years. 
The patient presented with a three-day history of dyspnea on exertion, now occurring at rest on 
the day of presentation.  He denied productive cough or hemoptysis.  He denied chest pain, 
nausea, vomiting, abdominal pain, change in bowel habits, or dysuria.  He denied arthralgia, 
photosensitivity, Raynaud’s phenomenon, ocular symptoms, mucosal ulceration, alopecia, or 
pleurisy.  He denied rash, weakness, or paresthesia.  He did endorse worsening bilateral foot 
pain for about one month prior to presentation, with the pain especially severe on the right.  He 
denied typical symptoms of claudication.  For 2 days prior to admission, the pain had been 
especially s vere:  present at rest, dull in nature, and non-radiating.    
Past medical history and medications 
The APS diagnosis was made at the age of 22, when he presented with an extensive left lower 
extremity deep venous thrombosis (DVT) event involving the left common femoral, popliteal, 
and peroneal veins.  He had two recurrences in the same extremity within two years, both 
apparently in the setting of sub-therapeutic anticoagulation with warfarin. 
Around age 30, he developed intermittent discoloration of his feet, more notable on the right, as 
well as hypocomplementemia and thrombocytopenia:  C3 of 74 (normal range 83-240 mg/dl), 
C4 of 11 (normal range 13-60 mg/dl), and platelets of 90,000/µl.  Aspirin 81 mg daily and 
hydroxychloroquine 400 mg daily were added to his warfarin therapy.  The hydroxychloroquine 
was added by his rheumatologist given the hypocomplementemia, although there were no 
symptoms beyond these lab abnormalities to suggest a diagnosis of lupus.  At this time, his 
hematologist also began monitoring and adjusting his warfarin dosing based on chromogenic 
factor X assay, rather than the INR, given concern that the lupus anticoagulant was interfering 
with INR monitoring.  The clinical and lab abnormalities all normalized with these various 
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medication adjustments.  Also around this time, CT angiography of the lower extremities 
demonstrated peripheral arterial disease, moderate-to-severe in the distal right common iliac 
artery and extending to the proximal right external iliac artery.  Mild narrowing of the distal left 
common iliac artery was also present.  Regarding risk factors for atherosclerosis in this 30-year-
old man, there was no evidence of dyslipidemia or human immunodeficiency virus on multiple 
lab tests.  The patient had also never been exposed to regular corticosteroids.  Transthoracic 
echocardiography at that time showed mild mitral regurgitation with no evidence of vegetation 
on good quality imaging. 
At age 31, he developed tonic-clonic seizures, which were subsequently well controlled with 
levetiracetam.  Migraine headaches ensued and persisted.  His doctors felt that both the 
seizures and migraine headaches could be attributable to APS, but there was no definitive 
proof. 
At age 35, he developed a difficult-to-heal left lateral malleolar ulceration, first emerging after 
minor trauma.  Given concerns about fluctunating INR testing and an inability to obtain 
chromogenic factor X levels locally, he was switched by his local physicians to the factor Xa 
inhibitor rivaroxaban.  It appears that rivaroxaban was chosen over low-molecular weight 
heparin primarily because of patient preference.  The ulceration was an on-and-off issue for the 
next two years, and was managed primarily by the wound clinic.  Although the location was a bit 
unusual, the prevailing opinion was that the ulcer was based in venous stasis more so than 
arterial insufficiency.  His course was otherwise stable.  There were no new thrombotic events 
or notable lab abnormalities (such as hypocomplementemia or thrombocytopenia).  His seizure 
disorder was stable.  He continued to work. 
Although the patient lacked a symptom history to suggest a concomitant diagnosis of lupus (no 
arthritis, serositis, glomerulonephritis, or lupus-specific rash), “lupus labs” were obtained from 
time to time over the years.  These revealed borderline positive testing for antinuclear antibody 
by HEp-2 assay and anti-double-stranded DNA by radioimmunoassay (anti-dsDNA, see below 
for more details).  Extractable nuclear antigen testing was consistently negative for anti-SSA, 
anti-SSB, anti-RNP, anti-Sm, and-SmRNP, anti-chromatin, anti-RiboP, anti-centromere, anti-
Scl70, and anti-Jo-1.  Complement levels tended to be normal with the exception mentioned 
above. 
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Social and family history  
There was no family history of systemic autoimmunity, inflammatory arthritis, coagulation 
disorders, cardiovascular disease, or malignancy.  He was a university graduate, employed, and 
married with two children.  He denied smoking or the use of illicit drugs, and reported drinking 
alcohol occasionally.   
Physical examination 
Exam on presentation to the hospital was notable for tachycardia (129 beats per minute), 
tachypnea (36 breaths per minute), hypoxemia (83% on room air), and fever (38.5ºC).  
Pulmonary exam demonstrated decreased breath sounds and coarse crackles at the bilateral 
bases.  On cardiovascular exam, normal first and second heart sounds were noted with no 
appreciable rubs, gallops, or murmurs.  Dorsalis pedis, posterior tibialis, and popliteal artery 
pulses were absent bilaterally.  Femoral pulses were faint.  He was noted to have a 2 cm x 3 cm 
left lateral malleolar ulceration that was stable compared to exam one month prior.  Additionally, 
the right first, second, and third toes demonstrated evidence of necrosis, compared to pinkish 
discoloration on recent outpatient exams.  
Lab testing and radiology 
His historical labs were notable for a prolonged dRVVT at 146.6 seconds (normal <42.9), 
dRVVT ratio 2.1 (essentially an assessment of phospholipid quenching, normal <1.19), and 
hexagonal phospholipid neutralization assay prolonged at 144 seconds (normal <7.9).  While he 
was on warfarin at the time of this testing, the hexagonal assay involves mixing 1:1 with normal 
plasma, and prolongation due to factor deficiency is therefore unlikely.  IgG anticardiolipin was 
>100 (normal <22 GPL), and IgG anti-β2GPI was >100 (normal <20 SGU).  Additionally, 
antinuclear antibody (ANA) testing was positive at a titer of 1:80 by HEp-2 immunofluorescence 
assay, with a speckled pattern.  Over the years, transient hypocomplementemia was once 
present (as above).  He had also had slight elevations in anti-dsDNA antibodies in the 30s 
(normal range <7.0 IU/mL).  Urinalysis was typically bland through the years, albeit with a mildly 
elevated urine protein:creatinine ratio of 0.26 (normal range <0.18). 
In the acute setting, laboratory results were notable for total white blood cell count of 15,000/µl 
with neutrophilia of 12,900/µl, new normochromic normocytic anemia (hemoglobin 9.5 g/dl, 
decreased from a baseline of 13 g/dl), and new thrombocytopenia (platelets 68,000/µl, 
decreased from a recently normal baseline).  Peripheral blood smear did not show evidence of 
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microangiopathy.  Haptoglobin, ferritin, fibrinogen, and D-dimer were all normal.  A 
comprehensive metabolic panel was notable for newly elevated creatinine of 1.64 mg/dl, blood 
urea nitrogen of 40 mg/dl, and a slight increase in aspartate aminotransferase from 32 to 57 
IU/l.  Lactate was normal on presentation.  Urinalysis was bland with no dysmorphic red blood 
cells.  Urine protein-creatinine ratio showed a slight increase from 0.26 to 0.46 (normal <0.18).  
The erythrocyte sedimentation rate (ESR) was 53 mm/hour, and the C-reactive protein (CRP) 
was 15.2 mg/dl (normal <0.6).  Both of these tests had been recently normal.  Complements C3 
and C4 were low at 59 mg/dl and 5 mg/dl, respectively.  Anti-dsDNA was positive at a level of 
65 IU/ml (the hospital laboratory had recently changed from a radioimmunoassay to an ELISA-
based assay, with 30-75 on the new assay considered “borderline positive”).  Troponin was 
elevated at 12.77 ng/mL (normal range <0.29), trending down to 9.86 ng/mL over the next 48 
hours. Blood cultures (both bacterial and fungal) were negative.   
Portable chest X-ray demonstrated bilateral patchy opacities.  Chest CT angiography (Figure 1) 
showing extensive multifocal patchy and ground-glass airspace opacities most pronounced at 
the lung bases where there was partial consolidation, left greater than right.  There was no 
evidence of pulmonary embolism.  Electrocardiogram showed sinus tachycardia, possible left 
atrial enlargement, and RSR' or QR pattern in V1 suggestive of right ventricular conduction 
delay.  Transthoracic echocardiogram showed a new (as compared to a study six years prior) 
and severe decrease in left and right ventricular function, a dilated inferior vena cava, and 
worsening mitral regurgitation (previously mild, now moderate).  Right ventricular systolic 
pressure was estimated at 33 mmHg with right atrial pressure of 10 mmHg; there was no 
evidence of tricuspid valve abnormality.  Abdominal and retroperitoneal ultrasounds with 
Doppler wer  normal.  Bilateral ankle-branchial indices were normal; however, an abnormality 
was noted on toe-brachial indices.  
 
CASE SUMMARY  
This is a 37-year-old man, who carries a diagnosis of primary APS with presumed associations 
including:  recurrent deep vein thrombosis complicated by post-thrombotic syndrome and 
ulceration; lower extremity atherosclerotic disease predisposing to toe ischemia; episodic 
thrombocytopenia; and seizure disorder.  At the time of presentation, he was being treated with 
rivaroxaban, aspirin, and hydroxychloroquine.  He presented with dyspnea, fever, hypoxemia 
with bilateral pulmonary ground glass opacities, worsening toe ischemia, systolic cardiac failure, 
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renal failure, normochromic normocytic anemia, and thrombocytopenia.  There was no evidence 
of hemolysis or disseminated intravascular coagulation, as demonstrated by normal haptoglobin 
and lack of schistocytes on peripheral blood smear.  
 
DIFFERENTIAL DIAGNOSIS 
Catastrophic antiphospholipid syndrome (CAPS) 
APS is an autoimmune disease characterized by thrombosis and pregnancy loss (1).  The 
catastrophic variety of APS (CAPS) is diagnosed in the setting of multi-organ involvement, 
typically with microvascular thromboses on biopsy (2).  A definitive diagnosis is often only made 
in hindsight as histological confirmation of microvascular thrombosis is typically lacking at the 
time of presentation (3).  Here, there is indication of multiple compromised organs, including the 
hypoxemic respiratory failure, rising creatinine, rising troponin with reduction in cardiac function, 
and toe ischemia.  Pointing away from CAPS is the absence of definitive microthromboses 
(although with the caveat that such specimens are often difficult to obtain in critically ill patients).  
Further, some patients with CAPS will present with hemolysis and even microangiopathy, which 
this patient does not have. 
APS-associated diffuse alveolar hemorrhage  
The development of acute hypoxemia in an APS patient, hemoglobin drop, and new infiltrate on 
imaging should raise suspicion for diffuse alveolar hemorrhage.  This manifestation has been 
described in both primary APS and CAPS (4-6).  Interestingly, the pathophysiology of diffuse 
alveolar hemorrhage in APS is typically of inflammatory vasculitis/capillaritis, rather than 
thrombosis, even in patients with primary APS (5, 6).  Hemoptysis was absent here, although 
that will be the case for many cases of diffuse alveolar hemorrhage.  Diffuse alveolar 
hemorrhage is of course a rare entity and there may be other explanations for the hemoglobin 
drop and lung infiltrate in this patient. 
Lupus flare 
Despite a historical diagnosis that had been labeled as “primary APS,” it is warranted to assess 
for overlapping systemic autoimmunity, with lupus being the most common culprit. 
Thrombocytopenia and worsening hypocomplementemia both raise suspicion for lupus; 
however, these can also be seen at modest levels in primary APS (7).  Diffuse alveolar 
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hemorrhage can be seen in lupus, with secondary APS and thrombocytopenia as recognized 
risk factors for that complication (8).  Renal disease could be based in lupus glomerulonephritis, 
although this is unlikely in the absence of active renal sediment and with a negligible amount of 
proteinuria.  Further, his physicians had never diagnosed him with lupus, given the absence of 
clinical signs and symptoms (as discussed in detail above). 
Infectious or Libman-Sacks endocarditis 
The worsening of mitral regurgitation raises suspicion for endocarditis.  Further, primary APS is 
regularly associated with valvular vegetations, similar to those seen in patients with lupus (7, 9).  
Valvular vegetations can precipitate embolic phenomena (10), including ischemic events (11).  
The worsening of renal function could be the result of either frank embolic disease or 
endocarditis/immune-complex-mediated glomerulonephritis.  The foot pain and toe necrosis 
could be secondary to embolism.  Negative blood cultures point away (although do not rule out) 
infectious endocarditis. There were also no stigmata of peripheral embolic disease such as 
Janeway lesions or Osler nodes.  While transthoracic echocardiogram was negative, 
transesophageal echocardiogram (which would have been more definitive) was not performed. 
Thrombotic thrombocytopenic purpura (TTP) 
With new anemia, thrombocytopenia, and renal failure, TTP can be considered.  However, with 
no evidence of microangiopathy on blood smear, or hemolysis by biochemical parameters, this 
becomes less likely (4, 12).  
Sepsis/community acquired pneumonia 
Infectious pulmonary infiltrates culminating in sepsis could explain the presentation.  The 
worsening toe ischemia could potentially stem from poor perfusion in the setting of systolic heart 
failure.  Infection is also well known to trigger CAPS (13).  Anemia and thrombocytopenia could 
result from disseminated intravascular coagulation in the setting of sepsis, although the normal 
D-dimer and fibrinogen make this less likely. 
 
HOSPITAL COURSE 
The patient’s hypoxemic respiratory failure worsened, requiring intubation.  He developed 
hypotension that was initially reversible with intravenous fluid.  He received 
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piperacillin/tazobactam, vancomycin, and azithromycin as treatment for suspected pneumonia 
and sepsis.  From a rheumatologic perspective, he was managed as a possible case of CAPS 
with pulse-dose corticosteroids (methylprednisolone 1000 mg x2), heparin infusion, and plasma 
exchange (3).  Cultures obtained by mini broncho-alveolar lavage culture were negative. The 
mini broncho-alveolar was not sufficient to prove or disprove diffuse alveolar hemorrhage (i.e., 
classical assessment by serial lavage); that assessment was not performed for fear of 
decompensating the patient.  On the third day of admission, he was improving with minimal 
ventilator requirements (fraction of inspired oxygen 35%, positive end-expiratory pressure 5).  
He then developed sudden drop in systolic blood pressure requiring norepinephrine infusion.  
He developed ectopic beats, and amlodipine was added.  Cardiac arrest occurred within one 
hour of the initial blood pressure drop.  He could not be resuscitated. 
 
AUTOPSY 
The heart was enlarged in size at 630 grams (normal mean 350 grams), with broad areas of 
fibrosis seen both grossly and microscopically (Figure 2).  Although no acute ischemia was 
noted grossly, there were multiple areas of microscopic ischemia (Figure 2).  Coronaries were 
significantly and chronically stenosed with complete occlusion of the proximal left anterior 
descending artery and 90% of the left circumflex proximally.  Microscopically, there were diffuse 
atheromatous plaques with chronic inflammatory changes including lymphocytes infiltrating the 
adventitia of all three major coronary arteries (Figure 3).  The infiltrates were predominantly 
comprised of CD4+ lymphocytes.  Two firm orange-tan vegetations were present on the mitral 
valve (0.5 cm x 0.4 cm and 0.3 cm x 0.2 cm), along with one friable pink-tan vegetation on the 
aortic valve (1.5 cm x 1 cm).  Microscopically, the valves demonstrated sterile fibrinous 
vegetations with chronic inflammation (lymphocytes more so than neutrophils), which would be 
consistent with Libman-Sacks endocarditis (14), rather than infectious endocarditis (15).  
Determining the precise etiology of Libman-Sacks endocarditis (lupus versus APS) is probably 
not feasible, as noted in the literature (16).  The distal abdominal aorta and bilateral common 
iliac arteries were remarkable for moderate calcific plaques. 
The pulmonary parenchyma was markedly hemorrhagic and congested.  This was unlikely to be 
explained by post-resuscitation trauma given the widespread nature of the bleeding noted 
macroscopically (17).  Pulmonary arteries were free from thrombi.  Microscopically, the lungs 
had extensive acute intraalveolar hemorrhage and intraalveolar macrophages (no definitive 
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hemosiderin-laden macrophages were detected).  Some capillaries showed surrounding acute 
inflammation (Figure 4).  The alveolar septae had patchy fibrosis.  Focal areas of intraalveolar 
acute inflammation were seen.   Kidneys were notable for numerous sclerotic glomeruli, chronic 
interstitial inflammation, and tubular calcification.  The renal pathology was hard to delineate 
further given post-mortem changes.  With that caveat, there were no features to suggest active 
glomerulonephritis (as in lupus) or microangiopathy/intimal hyperplasia (as in APS).  The 
interstitial inflammation was likely nonspecific and related to either antibiotics (pipercillin-
tazobactam is notorious) or even atherosclerosis (18).  Although there was no evidence of 
thrombi, atherosclerosis, or vasculitis in the vessels at the base of the brain, there was brown-
yellow mottled discoloration near the left occipital horn of the lateral ventricle indicative of old 
ischemia.  The liver and spleen weighed 2300 grams (normal mean 1500 grams) and 320 
grams (normal mean 150 grams), respectively, with no evidence of thrombi in either. 
 
DISCUSSION 
Antiphospholipid syndrome is an autoimmune disease mediated by pathogenic autoantibodies 
(especially to the phospholipid-binding plasma protein β2GPI), which promote thrombo-
inflammatory outcomes by engaging cellular membranes (19).  As mentioned above, the 
hallmarks of the disease are obstetric complications and vascular thromboses, with both arteries 
and veins at risk (1, 20).  There are other associated (sometimes called “non-criteria”) 
manifestations of APS that cannot be explained by thrombotic events (21), such as 
thrombocytopenia, heart valve lesions, and seizures.  Further, patients with APS have an 
elevated risk of cardiovascular/coronary disease (22, 23), and accelerated atherosclerosis (24).  
APS has also occasionally been linked to a traditional small-vessel vasculitis, especially in the 
lung capillaries (5).  Other “named” vasculitides that have rarely been connected to 
antiphospholipid antibodies in the literature include polyarteritis nodosa and Takayasu’s arteritis 
(25-29). 
Speaking more broadly, the intersection of inflammation and coagulation pathways in APS is 
well-recognized, with the two going hand-in-hand to promote thrombotic events.  Several cell 
types may be activated by antiphospholipid antibodies including endothelial cells, platelets, 
monocytes, and neutrophils (19, 30, 31).  Mechanistically, antiphospholipid antibodies promote 
activation of both the endothelium (for example, upregulation of vascular adhesion molecules) 
and the complement cascade.  The result is recruitment of neutrophils and monocytes (which 
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may themselves be primed by antiphospholipid antibodies) to the vascular lumen, where they 
activate coagulation pathways and trigger thrombosis (32). 
In this patient, there is coronary disease that is well beyond what would be expected based on 
his age and known traditional risk factors.  The adventitial layer of the coronary arteries is 
strikingly infiltrated by lymphocytes.  Traditionally, the histopathological description of 
atherosclerosis is for lipid deposition, followed by stages of blood vessel wall thickening and 
finally fibrosis (33).  While inflammatory cells may infiltrate the adventitia in atherosclerosis, they 
especially surround the lipid-rich regions of the vessel wall (the intima) (34, 35).  Here, the 
histopathology and concentration of CD4+ lymphocytes in the adventitia is quite compelling (and 
reminiscent of what might be seen in conditions like giant cell arteritis).  We speculate that some 
element of frank coronary vasculitis contributed to this patient’s vessel wall derangements, 
resulting in significant, progressive stenosis of both the left anterior descending and left 
circumflex arteries.  To our knowledge, coronary vasculitis has not been previously described in 
APS.  Of course, an important comment is that even in the absence of definite clinical or 
histopathological features of lupus in this patient, we cannot completely rule out overlapping or 
emerging lupus.  For example, recent work by our group and others has shown a type I 
interferon signature in patients with primary APS (36, 37), similar to that seen in lupus, which 
could have implications for the emergence of lupus features over time.  Having said that, his 
cardiovascular findings and rapid development of multi-organ failure are well out of proportion to 
any solid clinical evidence for lupus here, and more likely relate to his well-established diagnosis 
of severe APS. 
Regarding other key pathologic findings, the valvular disease in this patient is characterized by 
fibrinous inflammation and calcification, which is typical of what has been described in APS (i.e., 
Libman-Sacks endocarditis) (38).  The diffuse alveolar hemorrhage here seems to be driven by 
a capillaritis, which has also been reported in APS (5, 6, 39). 
In summary, the patient had severe coronary disease, with no clear risk factors beyond the 
primary APS—and with pathology supporting a potential role for coronary vasculitis.  The APS-
related diffuse alveolar hemorrhage was the final stressor that set in motion the events that 
culminated in his death. 
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Figure 1  Multifocal patchy and ground-glass airspace opacities.  These are most pronounced 
at the lung bases where there is partial consolidation, left greater than right. 
Figure 2  Left ventricle, microscopic view.  Left panel:  broad areas of dense collagenous scar.  
Right panel:  subacute changes (in response to ischemia) with granulation tissue and early 
collagen deposition.   
Figure 3  Left anterior descending artery, microscopic view.  A, Focal complete luminal 
occlusion with dense intramural inflammatory response, especially prominent at the media-
adventitia interface.  There is a predominance of CD4+ lymphocytes (B), with less CD8+ 
lymphocytes (C) and natural killer (NK) cell (D) infiltration.   
Figure 4  Pulmonary capillaritis, microscopic view. 
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